Consequently, strategies such as bariatric surgery, GLP-1 analogues and dipeptidyl peptidase-IV inhibitors (that increase the activity of GLP-1) to augment circulating GLP-1 availability/action are of great interest for the prevention/treatment of obesity and obesity-related diseases [1]. This evidence concerns the gene GCG and obesity disorder.